Chiesi Group

Crown CRO is a privately owned Finnish CRO founded in 2005. Our headquarters are in Espoo, which is located in Finland’s capital city region. Crown CRO offices are located in Finland, Sweden, Denmark, Norway, Estonia, Latvia and Lithuania. We have ongoing trials managed by our employees in Netherlands, Belgium, UK, Iceland, Ukraine and Belarus. Rest of the Europe and USA we cover through our qualified CRO network.

Our services cover Phase I – IV clinical development from protocol design to final reporting or any parts of the trial in various business models. Data services, Regulatory consulting, Pharmacovigilance, QA, Study Rescue Services and Medical Translation services complete the service package.

Our key therapeutic areas include, but not limited to, CNS, Oncology, Endocrinology, Cardiovascular, Respiratory and Musculoskeletal. We also have strong recent experience in Medical Devices from various indications.

Our passion for research across all our in-house Full-Service functions provide effective and innovative solutions with seamless cooperation for Phase I-III trials in Europe offering special focus on Nordic-Baltic area, together with our own Global Data Services ensuring consistency regardless of where your trials are located, offer you unrivalled customer attention, flexibility and high local level expertise which are key assets you can count on.

See www.crowncro.com for more information.

Founded in 1997, Ergomed plc is a global provider of high-quality services to the biopharmaceutical industry, spanning all phases of clinical trials, post-approval pharmacovigilance, and medical information. Ergomed’s fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and Ergomed Clinical Research, a complete, global Phase I-IV clinical development and trial management services with a strong heritage in the development of drugs in rare diseases and oncology.

• 1 300+ highly qualified professionals
• Global full-service CRO
• 24+ years of experience
• Therapeutic specialization in oncology
• Strong expertise in rare disease trials
• Robust clinical safety system
• Choice of leading drug safety databases

Our key services include:
• Clinical Research Services
• Pharmacovigilance
• Medical Information
• Regulatory
• Medical Writing
• Site Management
• Study Physician Support
• Biostatistics
• Patient Study Support

Fountain Medical Development is a clinical contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services in China, US, Japan, and Europe. FMD has extensive global experience in multiple therapeutic areas. The company has completed dozens of registrations trials which supported marketing authorization applications in US and Europe.

Our people is the basis of our success. The 1,700+ professionals are dedicated and diverse. At any given moment, at least 3 languages are spoken in our 20 offices in Asia, US, and Europe.

FMD is on the forefront of the paradigm shift in global clinical development. The regulatory reform in China has the potential to fundamentally change how an innovative therapy is developed. FMD is on the frontline building and shaping the future.

FMD is large enough to serve 7 out the 10 largest Pharma companies, and nimble enough to customize to the needs of startup firms.

In the US and Europe, FMD is doing business as FMD K&L. In China, we operate under the name FMD. Whatever the names are, the company is managed globally by a seasoned senior management team comprised of industry veterans.

Together we build a bright future.

We are a global healthcare intelligence partner, consistently ranked among the top CROs and best employers worldwide.
We help develop life-saving and life-improving drugs with our comprehensive clinical development services, including data management, statistical analysis, clinical trial management, medical writing, and regulatory and drug development consulting.

ArcDia International Ltd provides the most complete solutions for acute infection diagnosis with our mariPOC rapid antigen tests. Our aim is to promote healthier living and improved health care processes for respiratory and gastrointestinal infections such as COVID-19, influenza, RSV, CDI and many more.

The mariPOC platform is based on antigen detection using sandwich immunoassay principle and two-photon excited fluorescence assay technique. Thanks to the unique and proprietary technology, the platform provides automation, ease-of-use, multianalyte capability, cost-efficiency and high performance.

With more than 10 years of experience in the in vitro diagnostics industry, ArcDia is an ISO 13485 certified company providing our mariPOC test system for global distribution. Our high-tech Nordic diagnostic solutions are made in Turku, in the heart of Finland’s health industry. Our product portfolio also includes mariAST (RUO), a solution for tackling antibiotic resistance by speeding up antimicrobial susceptibility testing and mariCloud, an on-line service for real-time epidemiological surveillance. ArcDia envisions a healthier planet by facilitating correct diagnosis and treatment, avoiding unnecessary antibiotics and enabling a faster recovery.